Can a quick shot stop a heart attack in its tracks?

NCT ID NCT03487445

Completed Disease control Sponsor: Viatris Innovation GmbH Source: ClinicalTrials.gov ↗

First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether a single injection of selatogrel can rapidly prevent platelets from clumping together in adults having a heart attack. Participants receive either an 8 mg or 16 mg dose in the thigh, and researchers measure how quickly platelet activity drops. The goal is to see if this drug could provide a fast, easy way to reduce clot formation during a heart attack.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an injectable drug called selatogrel that prevents platelets from clumping together
What this could lead to: If it works, selatogrel could offer a fast-acting, easy-to-give treatment for heart attacks, potentially reducing damage to the heart.
What could go wrong: This is an early-phase trial with only 48 participants, so results may not apply to everyone. The drug may not work fast enough or could cause bleeding risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYOCARDIAL INFARCTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYOCARDIAL INFARCTION

Contacts and locations

Locations

Cardiocentro Ticino

Lugano, 6900, Switzerland
Galilee Medical Center

Nahariya, 22100, Israel
OLV Ziekenhuis Aalst

Aalst, 9300, Belgium
UZLeuven

Leuven, 3000, Belgium
University Hospital Bern

Bern, 3010, Switzerland
Universitätsspital Basel

Basel, 4031, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.